Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
PMLiVE6d
Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug
The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...
ThePrint14d
PopVax Announces 1.15 Million USD in Funding from the Bill and Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
Show Full Article The Principal Investigator for this project is Dr. Maunish Barvalia, PopVax’s Vice President of Platform Technologies, who previously worked with pioneering nucleic acid delivery ...
Webindia 12314d
PopVax Announces 1.15 Million USD in Funding from the Bill and Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
who previously worked with pioneering nucleic acid delivery research groups at NanoVation Therapeutics and during his PhD at the University of British Columbia in Canada. "We at PopVax are ...